These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31102693)

  • 1. Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.
    Sang Y; Han S; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2019 Aug; 89():102974. PubMed ID: 31102693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
    Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Jan; 185():111874. PubMed ID: 31735575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.
    Huang WJ; Pannecouque C; De Clercq E; Wang S; Chen FE
    Eur J Med Chem; 2024 Oct; 276():116668. PubMed ID: 38996652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yan ZH; Huang XY; Wu HQ; Chen WX; He QQ; Chen FE; De Clercq E; Pannecouque C
    Bioorg Med Chem; 2014 Apr; 22(8):2535-41. PubMed ID: 24680058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.
    Lei Y; Han S; Yang Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32111013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
    Ding L; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    J Med Chem; 2021 Apr; 64(8):5067-5081. PubMed ID: 33851529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
    ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
    Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Wu HQ; Yan ZH; Chen WX; He QQ; Chen FE; De Clercq E; Balzarini J; Daelemans D; Pannecouque C
    Bioorg Med Chem; 2013 Nov; 21(21):6477-83. PubMed ID: 24055077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.
    Li X; Chen W; Tian Y; Liu H; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Eur J Med Chem; 2014 Jun; 80():112-21. PubMed ID: 24769349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
    Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
    Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Gu SX; He QQ; Yang SQ; Ma XD; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Sep; 19(17):5117-24. PubMed ID: 21824782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors.
    Ma XD; Yang SQ; Gu SX; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    ChemMedChem; 2011 Dec; 6(12):2225-32. PubMed ID: 21990112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I.
    Kang D; Wang Z; Chen M; Feng D; Wu G; Zhou Z; Jing L; Zuo X; Jiang X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Chem Biol Drug Des; 2019 Apr; 93(4):430-437. PubMed ID: 30381875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.